In the domain of pharmaceuticals, we need a metric for…
“In the domain of pharmaceuticals, we need a metric for health impact, and with this metric we can then assess the value of the introduction of a new product and pay its innovator accordingly, say on the basis of the product's measured health impact during its first ten years on the market. In exchange, innovators must of course renounce the usual rewards they are otherwise entitled to, namely the patent-protected markup on the price of their product.”
About This Quote
This interpretation was drafted with AI assistance. It is one reading of the quote, not the author's own explanation.
Advocates a health‑impact metric to reward innovators based on societal benefit rather than profit, proposing patent‑markup sacrifice.
In simple terms: Reward health impact, not profit.
Key Takeaway
Shift incentives to health outcomes.
Themes
health policy
innovation
ethics
economics
patents
Mood
critical
thought‑provoking
Type
policy
economic
When to use this quote
- government health agencies
- pharma R&D
- NGO funding models
Key Concepts
public health metrics
fair compensation
social welfare
Questions to Reflect On
- How to accurately measure health impact?
- What safeguards prevent abuse of the system?
A Different Perspective
Implementation complexity and measurement accuracy are challenging.